Proposed Trial Would Be First Ever for Novel Two-Pronged Immunotherapy Strategy
November 13th 2015
Roswell Park Cancer Institute is taking
the final steps toward what we believe would be
the first-ever clinical trial combining two novel
and highly promising techniques: adoptive cellular
therapy utilizing re-engineered mature
T cells and re-engineered adult hematopoietic
stem cells.